A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
← catalyst calendarNCT05877599 · readout in 1,077 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
45estimated
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-12 | actual | When the study began enrolling |
| Primary completion | 2029-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Colorectal Carcinoma
- Pancreatic Adenocarcinoma
- Breast Cancer
- Other Solid Tumors
- Ovarian Cancer
- Myeloid Neoplasms (AML/MDS)
Intervention
- Biological: NT-175
Primary outcomes
what the primary-completion date above is the date OFModule 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
measured 28 days after infusion
Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
measured Up to 24 months post-infusion
Module 1, Part 2: Preliminary anti-tumour activity of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
measured Up to 24 months after infusion
Module 2: Safety of NT-175 in participants with haematological malignancies
measured Up to 28 days after infusion
Module 2: Safety of NT-175 in participants with haematological malignancies
measured Up to 24 months after infusion
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed